Wall Street Zen upgraded shares of Sutro Biopharma (NASDAQ:STRO – Free Report) from a strong sell rating to a sell rating in a report issued on Monday morning,Wall Street Zen reports.
A number of other equities research analysts have also recently commented on STRO. Weiss Ratings upgraded Sutro Biopharma from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Mizuho upgraded shares of Sutro Biopharma to a “strong-buy” rating in a research note on Wednesday, September 16th. Citigroup reissued a “market outperform” rating on shares of Sutro Biopharma in a research report on Thursday, August 13th. Citizens Jmp decreased their price objective on shares of Sutro Biopharma from $41.00 to $34.00 and set a “market outperform” rating for the company in a report on Thursday, August 13th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $60.00 price objective on shares of Sutro Biopharma in a research report on Thursday, October 15th. Two investment analysts have rated the stock with a Strong Buy rating, ten have given a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $49.60.
Sutro Biopharma Trading Down 5.1%
STRO opened at $9.32 on Monday. The company has a market cap of $154.53 million, a P/E ratio of -0.78 and a beta of 1.56. The business’s 50-day moving average price is $12.96 and its 200-day moving average price is $22.51. Sutro Biopharma has a 12 month low of $7.15 and a 12 month high of $43.85.
Sutro Biopharma (NASDAQ:STRO – Get Free Report) last announced its quarterly earnings results on Thursday, November 12th. The company reported ($1.90) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.64) by ($0.26). The company had revenue of $9.10 million during the quarter, compared to the consensus estimate of $14.11 million. Equities research analysts forecast that Sutro Biopharma will post -8.12 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Sutro Biopharma
A number of hedge funds have recently bought and sold shares of the business. Orbimed Advisors LLC bought a new position in shares of Sutro Biopharma in the first quarter worth about $19,956,000. Perceptive Advisors LLC bought a new stake in Sutro Biopharma during the 1st quarter valued at about $17,818,000. ADAR1 Capital Management LLC lifted its holdings in Sutro Biopharma by 681.8% during the 1st quarter. ADAR1 Capital Management LLC now owns 524,441 shares of the company’s stock valued at $13,064,000 after buying an additional 457,364 shares in the last quarter. Goldman Sachs Group Inc. boosted its position in Sutro Biopharma by 232.9% in the 3rd quarter. Goldman Sachs Group Inc. now owns 496,794 shares of the company’s stock valued at $8,003,000 after buying an additional 347,578 shares during the period. Finally, Affinity Asset Advisors LLC boosted its position in Sutro Biopharma by 42.9% in the 1st quarter. Affinity Asset Advisors LLC now owns 1,069,519 shares of the company’s stock valued at $26,642,000 after buying an additional 321,137 shares during the period. Hedge funds and other institutional investors own 96.99% of the company’s stock.
About Sutro Biopharma
Sutro Biopharma is a biotechnology company focused on discovering and developing targeted cancer treatments. Its research has centered on antibody-drug conjugates (ADCs), which use antibodies to deliver cancer-fighting drugs to selected cells. The company developed its XpressCF+ platform, a cell-free protein synthesis and site-specific conjugation technology intended to support the design and production of biologic medicines. Sutro’s clinical-stage programs have included luveltamab tazevibulin, an ADC targeting folate receptor alpha, and STRO-003, an ADC targeting ROR1.
Featured Articles
- Five stocks we like better than Sutro Biopharma
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Sutro Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sutro Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.
